Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Business Case for Expanded Clozapine Utilization.

Jessica L Gören1, Adam J Rose1, Eric G Smith1

  • 1Dr. Gören is with the Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston (e-mail: jgoren@challiance.org ). She and the other authors are also with the Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts. Dr. Rose is also with the Department of Medicine, Boston University, Boston. Dr. Smith is also with the Department of Psychiatry, University of Massachusetts Medical School, Worcester. Dr. Ney is also with the Department of Neurology, Boston University, Boston.

Psychiatric Services (Washington, D.C.)
|June 16, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infection-induced glucose starvation triggers NINJ1-dependent macrophage lysis and Candida escape.

Nature communications·2026
Same author

The expanding landscape of the glucagon signaling network: mechanisms and outcomes.

Endocrinology·2026
Same author

A nutrient-hormone axis pivots an energy trade-off between resting thermogenesis and movement expenditure.

Journal of sport and health science·2026
Same author

After 6 Decades of Blood Pressure Management, Why Is Achieving Control Still So Difficult?

Journal of general internal medicine·2026
Same author

Blood Pressure and Low-Density Lipoprotein Cholesterol in Stroke Survivors Versus Controls in the United States From 1999 to 2018.

Stroke (Hoboken, N.J.)·2026
Same author

The majority of opioid prescriptions in Israel between 2010 and 2020 involved a small minority of physicians and of patients: policy implications.

Israel journal of health policy research·2025

Increasing clozapine use for treatment-resistant schizophrenia can save healthcare costs. This analysis shows significant savings for the Veterans Health Administration by increasing clozapine utilization in patients with treatment-resistant schizophrenia.

Area of Science:

  • Pharmacoeconomics
  • Psychiatry
  • Health Services Research

Background:

  • Clozapine is the sole effective treatment for treatment-resistant schizophrenia, yet its utilization remains below 25% in most healthcare settings.
  • A significant gap exists between the proven efficacy of clozapine and its actual prescription rates for treatment-resistant schizophrenia.

Purpose of the Study:

  • To conduct a business case analysis evaluating the potential for direct healthcare cost savings within the Veterans Health Administration (VHA) by increasing clozapine utilization for treatment-resistant schizophrenia.
  • To assess the economic impact of expanding clozapine therapy for patients with treatment-resistant schizophrenia.

Main Methods:

  • A systematic review of published studies was used to gather data on treatment response, suicides, adverse drug reactions, mortality, and inpatient hospitalization effects associated with clozapine.

Related Experiment Videos

  • Economic modeling included a one-factor sensitivity analysis and a probabilistic sensitivity analysis (PSA) utilizing Monte Carlo simulation to determine the cost-benefits of enhanced clozapine use.

    • Main Results:

    • The base case analysis projected savings of $22,444 per veteran with treatment-resistant schizophrenia in the first year of clozapine therapy, mainly due to reduced inpatient days.
    • Doubling current clozapine utilization and achieving a 50% continuation rate for one year could yield an estimated $80 million in VHA savings.
    • Probabilistic sensitivity analysis indicated potential savings of at least $290 million in 95% of simulations if clozapine were initiated for all eligible VHA patients.

    Conclusions:

    • Increased utilization of clozapine for treatment-resistant schizophrenia is projected to generate substantial net cost savings for the Veterans Health Administration.
    • The findings support a strategic initiative to broaden access to clozapine for eligible patients to improve outcomes and reduce healthcare expenditures.